Latest Research Development News

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

DroneShield is investing $13 million to significantly expand its R&D and manufacturing footprint, aiming to boost annual production capacity nearly fivefold by the end of 2026.

Anatara Lifesciences has strengthened its intellectual property portfolio with a Japanese patent for its GaRP gastrointestinal health product, while progressing pre-clinical studies in its Anti-Obesity Project. The company also confirmed registration of its R&D Tax Incentive application for 2024-2025.

AdNeo Limited’s shares are back on the ASX following the completion of a capital raising, ending a trading suspension that had investors waiting. The biotech company’s next moves will be closely watched as it seeks to leverage fresh funds.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Sparc Technologies has successfully closed its Share Purchase Plan, raising more than double its initial target, signaling strong shareholder confidence as it advances its green hydrogen and graphene projects.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Elixir Energy has successfully closed its Share Purchase Plan, raising an additional $117,000 and bringing total capital raised to $7.1 million, supported by new shares and free attaching options.